The global cancer biopsy market size was estimated at USD 25.54 billion in 2021 and is projected to reach USD 59.39 billion by 2030, growing at a CAGR of 17.6% from 2022 to 2030.
The global cancer biopsy market size was estimated at USD 25.54 billion in 2021 and is projected to reach USD 59.39 billion by 2030, growing at a CAGR of 17.6% from 2022 to 2030.
Biopsy is the most common way for the doctors to diagnose cancer. It is a confirmatory test for cancer, and other tests can only indicate the presence of cancer. A small piece of tissue is taken for examination under a microscope in order to detect the cancer. The increased prevalence of cancer and the growing desire for the non invasive treatment will lead to an increase in the growth of the cancer biopsy market during the forecast period.
In order to decide the patient’s treatment plan, the results of the biopsy are useful. The use of liquid biopsy for the personalized medicine ensures that the market will grow favorably. In order to ensure that the medications are targeted and actionable, personalized medicines can be used.
Get a Free Sample Copy of this Report@ https://www.precedenceresearch.com/sample/1514
Regional snapshot
The North American region is the largest segment for the cancer biopsy market. A good range of availability of technologically advanced instruments, well developed healthcare systems in US as well as Canada and the existence of various prominent clinical laboratories have helped in the market growth. The Asia Pacific regional expansion in the cancer biopsy market will be aided due to the increased cancer patients, the highly upgraded infrastructure and the quick adoption of all the advanced methods. As there is a growing demand for noninvasive illness detection, the segment is expected to grow. New products are launched by various market players by focusing on research and development.
| Report Scope | Details |
| Market Size in 2030 | USD 66.1Billion |
| Growth Rate from 2021 to 2030 | CAGR of 17.6% |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
Market dynamics
Drivers
In order to make the treatment decisions for the patients, which are based on their response to a therapy, the companion diagnostics test are used. The combination of companion diagnostics with therapeutic goods has the potential to modify the drug development procedure and commercialize the drug candidates by swiftly and cost effectively delivering the medications with efficiency. Due to the rising need for high priced specialist therapies and safe medications the market for the companion diagnostics is expected to grow. Thus leading to an increase in the growth of the global cancer biopsy market during the forecast.
Restraints
The procedure of paying for the costly molecular testing and the needed expertise of the various professionals to interpret the results and to develop the treatment programs is inefficient and it is very complicated. In the developing nations, the process of paying for these tests is extremely costly and inconvenient. Liquid biopsy is an expensive technology, so these are the factors that are restricting the market growth.
Ask Here for Customization@ https://www.precedenceresearch.com/customization/1514
Opportunities
Every year there is a rise in the number of patients diagnosed with cancer across the world. The various reasons for the rise in these numbers is the environmental causes, hepatitis B,C infection, cigarette consumption and the changes in the lifestyle. The treatment for cancer with biopsy includes advantages of reduces cost therapy, monitoring, early prognosis, patient comfort, the detection of tumor heterogeneity and the acquired drug resistance. Due to the development of various types of cancer in patients across the world many opportunities are created for the growth of the global cancer biopsy market during the forecast.
Challenges
There are occasional chances of failure in detecting the lesions or determining the extent of illness in case of the less invasive breast biopsy. If the diagnosis remains questionable followed by a technically effective treatment the surgical biopsy is needed. These limitations of the biopsy are creating obstacles and hindering the growth of the cancer biopsy market.
Report highlights
- In terms of application, breast cancer segment dominated the cancer biopsy market in 2020 and it is expected to grow throughout the forecast.
- Based on the product segment, the kits and consumables accounted for the biggest share in the year 2020, reasons being considerable movement from tumor to liquid biopsy with the help of these kits and consumables.
- On the basis of the segment type, the tissue biopsy segment is expected to grow during the forecast period and it has dominated the global cancer biopsy market in the year 2020. In order to diagnose cancer, tissue biopsies are commonly used. Tissue biopsies are also used to diagnose infections, inflammatory diseases and autoimmune illnesses.
Recent Developments
The US Food and Drug Administration approved the first liquid biopsy in August 2020, which is GUARDANT 360 CDx,it is said to be the next generation sequencing companion diagnostic test. It is a product of Quadrant Health Inc.
In the year 2020, Hologic acquired Somatic’s, which is a medical device manufacturing company, it specializes in manufacturing minimally invasive disposable instruments, biopsies and breast care.
Quick-core auto biopsy system for the biopsy procedure was launched in March 2021 by IZI Medical products. It is a fully automated product which is built on the company’s proprietary semi-automatic system which is quick core
Some of the key players in the market include:
- Myriad Genetics Inc.
- Guardant Health Inc.
- Exact Sciences Corporation
- Bio-Rad Laboratories Inc.
- Agena Bioscience Inc.
- Personal Genome Diagnostics Inc.
- Exosome Diagnostics Inc.
- ANGLE Plc.
- F. Hoffmann-La Roche Ltd.
Market Segmentations:
By Product
- Instruments
- Kits and Consumables
- Services
By Type
- Tissue Biopsies
- Fine Needle Aspiration (FNA)
- Core Needle Biopsy (CNB)
-
- Needle Biopsies
- Surgical Biopsies
- Liquid Biopsies
- Others
By Application
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Click Here to View Full Report Table of Contents
Buy this Research Report@ https://www.precedenceresearch.com/checkout/1514
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333